Monday, December 7, 2015

UNAids, Comesa partner on drugs in EA


The two organisations aim at increased production of affordable medicine by the private sector in the region. PHOTO | FILE
The two organisations aim at increased production of affordable medicine by the private sector in the region. PHOTO | FILE 
By CHRISTABEL LIGAMI
In Summary
  • The two organisations aim at increased production of affordable medicine by the private sector in the region.
The Common Market for Eastern and Southern Africa (Comesa) and the United Nations Programme on HIV/Aids (UNAids) are working together to harmonise the production of medicines and related products in the region.
UNAids representative to the African Union Rosemary Museminali said the two organisations aim at increased production of affordable medicine by the private sector in the region.
Comesa Secretary General Sindiso Ngwenya said the strategy will help drive the current Comesa initiatives towards eventual production of pharmaceuticals in the region and Africa, which depends for more that 80 per cent of its needs on imported pharmaceutical and medical products.
Currently, Comesa is working on a co-operation framework among member states in the manufacturing of essential drugs and an amendment to the Trade Related Intellectual Property Rights (Trips) Agreement on compulsory licensing for medicine.
Early this year, the Council of Ministers agreed on the creation of a Comesa pharmaceutical working group to open a larger public private dialogue on encouraging investments and partnerships in the industry.
The Council urged states to hold pharmaceutical business round-tables with manufacturers, associations, policymakers and other stakeholders as an entry point for deeper engagement with the pharmaceutical industry on requirements for strengthening local production.
“The role of pharmaceutical companies in the healthcare system around the globe is indispensable especially in reducing the time spent in hospitals, thus improving the quality of life and human development,” said the Council. Currently, 38 members of the AU have some form of pharmaceutical production.
But they vary in product quality and the ability of the regulatory authorities to enforce standards. Manufacturers largely rely on imports for most of inputs.
Various challenges prevent the industry from scaling up production. These include steep investment requirements, the need for expertise and skilled workers, stringent quality standards as a prerequisite to access donor funded prequalified markets and cross border regulatory harmonization for regional markets.
In addition, there exists an uneven playing field for locally produced drugs against finished product imports.
The Comesa/UNAids partnership is ultimately aimed at enabling local production of pharmaceuticals which will advance industrial development, reduce external dependency, facilitate stronger regulatory oversight to curtail counterfeit products, improve the balance of payments through savings on foreign exchange and create job

No comments :

Post a Comment